Overall rank by patents
#24,807
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 11 technology areas, active 2018–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES).
The verdict
Mitegen holds 11 US patents across 11 technology areas, rank #24,807 of 50,000 tracked assignees.
Mitegen, Llc has been granted 11 US utility patents between 2018 and 2025, placing Mitegen, Llc at rank #24,807 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.9 claims per patent with primary concentration in G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES). As a US Corporation, Mitegen, Llc is one of the more focused assignees in the PatentsView dataset. By volume, Mitegen sits between Meike Technology (beijing) Ltd. (11 patents, rank #24,803) and Microvascular Tissues, Inc. (11 patents, rank #24,811) - the closest US assignees by grant volume. The composite Innovation Score of 52.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 9 grants, compared with 2 in the 2015–2019 window, a +350% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Mitegen, Llc's 20.9 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 11 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Mitegen, Llc against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Meike Technology (Beijing) Ltd.
11 patents
Merge Labs Inc.
11 patents
Meridian Innovation Pte Limited
11 patents
Metis Design Corporation
11 patents
MiZ Company Limited
11 patents
Michellia Inc.
11 patents
Micro Macro Assets, LLC
11 patents
MicroVascular Tissues, Inc.
11 patents
MiTeGen, LLC
11 patents
What this shows Mitegen holds 11 patents at rank #24,807, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Mitegen's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
53 Top 10% higher than 90% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 1 | 9.1% |
| 2019 | 1 | 9.1% |
| 2022 | 1 | 9.1% |
| 2023 | 2 | 18.2% |
| 2024 | 2 | 18.2% |
| 2025 | 4 | 36.4% |
Top 11 of 11 technology areas
Overall rank by patents
#24,807
Across all tracked assignees
52.9 out of 100
How to use this portfolio
Mitegen's 11 grants land it in the top 10% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.